CD8A and neoplasm: In mouse xenograft models of sarcoma, colorectal, and breast cancer, anti-TREM2+ monoclonal antibodies can selectively eliminate TAMs from the TME, increasing the infiltration of CD8+T cells in the TME and its effective function, thus promoting anti-tumor immunity (Molgora et al., 2020).